There is no large CML dataset available on the portal, however, analysis of acute leukaemic samples revealed a significant decrease in the median OS of patients with low FUBP3 expression (12.17 months) compared to those with high FUBP3 expression (15.46 months) (p = 0.0262) (Figure 2H). Here, FUBP3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.